TY - JOUR
T1 - The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma
AU - Chan, Sheng Chieh
AU - Hsu, Cheng Lung
AU - Yen, Tzu Chen
AU - Ng, Shu Hang
AU - Liao, Chun Ta
AU - Wang, Hung Ming
PY - 2013/1
Y1 - 2013/1
N2 - Objectives: To investigate the role of PET-derived imaging markers in predicting metastatic nasopharyngeal carcinoma (NPC) outcomes. Materials and methods: A total of 56 patients with metastatic NPC were enrolled. Before treatment, all of the participants underwent 18F-FDG PET/CT. The following 18F-FDG PET parameters were assessed: standardised uptake value, metabolic tumour volume (MTV), and total lesion glycolysis. Multivariate Cox proportional hazards models were used to identify the independent predictors of survival. Results: The multivariate analysis showed that performance status > 1 (P = 0.007), Epstein-Barr virus (EBV) DNA titre > 5000 copies/mL (P = 0.001), and MTV > 110 mL (P = 0.013) were independent risk factors for progression-free survival (PFS). Male sex (P = 0.004), performance status > 1 (P < 0.0001), EBV DNA level > 5000 copies/mL (P < 0.0001), and MTV > 110 mL (P = 0.003) independently predicted overall survival (OS). The 2-year PFS and OS rates of the patients with MTV ≤ 110 mL were 23.2% and 43%, respectively, compared with 0% and 9.1%, respectively, for those with MTV > 110 mL. Combining the MTV with the EBV DNA titre allowed further survival stratification by dividing the patients into three groups with distinct PFS (2-year rates = 30.8%, 7.1%, and 0%, P < 0.0001) and OS (2-year rates = 68.4%, 40%, and 0%, P < 0.0001) rates. Conclusion: The MTV appears to be an independent risk factor in metastatic NPC patients. This factor is complementary to the EBV DNA titre for predicting survival in metastatic NPC.
AB - Objectives: To investigate the role of PET-derived imaging markers in predicting metastatic nasopharyngeal carcinoma (NPC) outcomes. Materials and methods: A total of 56 patients with metastatic NPC were enrolled. Before treatment, all of the participants underwent 18F-FDG PET/CT. The following 18F-FDG PET parameters were assessed: standardised uptake value, metabolic tumour volume (MTV), and total lesion glycolysis. Multivariate Cox proportional hazards models were used to identify the independent predictors of survival. Results: The multivariate analysis showed that performance status > 1 (P = 0.007), Epstein-Barr virus (EBV) DNA titre > 5000 copies/mL (P = 0.001), and MTV > 110 mL (P = 0.013) were independent risk factors for progression-free survival (PFS). Male sex (P = 0.004), performance status > 1 (P < 0.0001), EBV DNA level > 5000 copies/mL (P < 0.0001), and MTV > 110 mL (P = 0.003) independently predicted overall survival (OS). The 2-year PFS and OS rates of the patients with MTV ≤ 110 mL were 23.2% and 43%, respectively, compared with 0% and 9.1%, respectively, for those with MTV > 110 mL. Combining the MTV with the EBV DNA titre allowed further survival stratification by dividing the patients into three groups with distinct PFS (2-year rates = 30.8%, 7.1%, and 0%, P < 0.0001) and OS (2-year rates = 68.4%, 40%, and 0%, P < 0.0001) rates. Conclusion: The MTV appears to be an independent risk factor in metastatic NPC patients. This factor is complementary to the EBV DNA titre for predicting survival in metastatic NPC.
KW - Epstein-Barr virus
KW - F-FDG PET/CT
KW - Head and neck cancer
KW - Metabolic tumour volume
KW - Metastasis
KW - Nasopharyngeal carcinoma
KW - Prognosis
KW - Standardised uptake value
KW - Total lesion glycolysis
UR - http://www.scopus.com/inward/record.url?scp=84871413555&partnerID=8YFLogxK
U2 - 10.1016/j.oraloncology.2012.07.016
DO - 10.1016/j.oraloncology.2012.07.016
M3 - 文章
C2 - 22959277
AN - SCOPUS:84871413555
SN - 1368-8375
VL - 49
SP - 71
EP - 78
JO - Oral Oncology
JF - Oral Oncology
IS - 1
ER -
